News

New commercial agreement for ViroScore® and DeepChek®

ABL inked a distribution agreement with Thermo Fisher Scientific for ViroScore and DeepChek, downstream analysis softwares for Sanger and Next Generation Sequencing respectively. These are also available on Thermo Fisher Cloud. See the press release.

Read more

ABL Group launches early access program

ABL group is pleased to announce the launch of an early access program (EAP) of its first genotyping DeepChek® assay for HCV NS5B. Further reagents will come soon to complete ABL Group’s offer for Sanger and Next Generation Sequencing. These reagents will be completed with data analysis software, Vi…

Read more

HepatiC® trademark registration

ABL is pleased to announce that its mark HepatiC® has now achieved registration with the United States Patent and Trademark Office on the Supplemental Register with N° 4,661,252. The HepatiC® software is a patient register to monitor HCV-infected patients in particular for ones using Direct Antivira…

Read more

DeepChek®-HBV and HCV Now Available in Illumina’s BaseSpace Apps

Two new DeepChek® applications dedicated to viral hepatitis B (HBV) and hepatitis C (HCV) are now available in BaseSpace, the Illumina’s dedicated applications store and cloud-based informatics community dedicated to advancing genomic analysis. See the press release about BaseSpace and Illumina.

Read more

Collaboration on HBV genomic variations and HCC

ABL is pleased to announce a new collaboration with the New Zealand Liver Transplant Unit and LabPlus at Auckland City Hospital. This will evaluate the susceptibility to develop Hepatocellular Carcinoma (HCC) during 30 years follow-up, based on key baseline genomic variations of HBV in a large cohor…

Read more
#